Testimony
Featured Topics
Lead story
Other featured articles
-
Ensuring Affordable and Valuable Pharmaceutical Innovation for Americans
Aligning drug prices with the actual value provided to patients stimulates innovation that benefits patients and discourages innovation that does not. Legislation to increase drug price transparency, coupled with better information about value, can help payers and consumers spend their money wisely.
Posted in -
Examining Policies that Inhibit Innovation and Patient Access
Americans have benefited substantially from new medical treatments, and the United States serves as the engine of medical innovation for the world.
Posted in -
Testimony on Pharmacy Benefit Managers and the Prescription Drug Supply Chain
Karen Van Nuys spoke to the Senate Finance Committee on March 30, 2023 about the role PBMs play in the pharmaceutical distribution system.
Posted in -
Testimony on Bringing Transparency and Accountability to Pharmacy Benefit Managers
Erin Trish spoke at the Senate Committee on Commerce, Science, & Transportation on February 16, 2023 about the complex and influential role that PBMs play in the pharmaceutical distribution system.
Posted in
ADDITIONAL TESTIMONY
-
Potential Impacts of Recreational Marijuana Policies and Regulatory Structures that Could Reduce its Negative Impacts
Rosalie Liccardo Pacula presented before the Florida House of Representatives Health & Human Services Committee, Subcommittee on Health Quality on Dec. 11, 2019 about regulations to govern the use of recreational marijuana.
-
Medicare Physician Payment Reform After Two Years: Examining MACRA Implementation and the Road Ahead
Matthew Fiedler spoke at the Senate Finance Committee on May 8 about the implementation of the Medicare physician payment provisions of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).
Categorized in -
Examining Surprise Billing: Protecting Patients from Financial Pain
Christen Linke Young delivered testimony to the House Education and Labor Subcommittee on Health, Employment, Labor, and Pensions on April 2, 2019.
Categorized in -
Testimony on Texas v. U.S.: The Republican Lawsuit and its Impacts on Americans with Pre- Existing Conditions
Christen Linke Young delivered testimony to the House Energy & Commerce Subcommittee on Health on February 6, 2019.
Categorized in -
Economic Aspects of the Opioid Crisis
Sir Angus Deaton testified on the decline in life expectancy in the United States and the role opioids have played in this startling trend.
-
Comments on CMS’s proposed rule for implementation of MACRA provisions
Paul Ginsburg and his colleagues suggest three ways in which CMS can further achieve its stated goal to “expand the opportunities for participation in APMs” by better supporting providers’ transition under MACRA.
Categorized in